Table 1.
Sample Demographics.
| Characteristic | Healthy Subjects | Schizophrenia Patients | Statistics | |
|---|---|---|---|---|
| n = 72 | n = 59 | χ 2 /t | p | |
| Gender (Male: female) | 49:23 | 49:10 | 3.87 | 0.049 |
| Smoking Status (Smoker: Non-smoker) | 15:56 | 20:39 | 2.67 | 0.102 |
| Age (years) | 35.86 ± 11.67 | 37.69 ± 13.77 | 0.81 | 0.419 |
| WTAR T-score | 109.02 ± 13.02 | 102.71 ± 13.50 | −2.59 | 0.011 |
| WASI VIQ | 106.75 ± 11.22 | 99.29 ± 16.67 | −2.93 | 0.004 |
| WASI PIQ | 114.23 ± 12.43 | 103.89 ± 16.23 | −3.88 | < 0.001 |
| WASI FSIQ (four subtest) | 111.79 ± 11.92 | 100.89 ± 16.87 | −4.10 | < 0.001 |
| Age at First Illness | 22.1 ± 8.74 | |||
| Duration of Illness (years) | 15.59 ± 12.09 | |||
| PANSS Positive | 14.66 ± 4.59 | |||
| PANSS Negative | 14.81 ± 5.03 | |||
| PANSS General | 29.12 ± 8.02 | |||
| CPZ Equivalents | 369.25 ± 318.69 | |||
WTAR, Wechsler Test of Adult Reading; Wechsler Abbreviated Scale of Intelligence (WASI); VIQ, verbal intelligence; PIQ, performance intelligence; FSIQ, full scale intelligence; PANSS, Positive and Negative Syndrome Scale; CPZ, chlorpromazine; p values < 0.05 are labelled in bold.